NEJM Voices brings together expert contributors to share informed opinions and personal perspectives on medicine, health, and patient care. https://www.nejm.org/browse/voices-series/paul-sax NEJM Group Sat, 20 Jun 2026 01:26:29 GMT 2026 NEJM Group en-us 1440 On the ritual, limits, and occasional magic of the daily physical exam. https://www.nejm.org/doi/full/10.1056/VOICESpost2600020?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/VOICESpost2600020 Paul E. Sax 2026-06-10 Heart, Lung, Abdomen, Ankles A recent federal announcement to combat tick-borne disease has a promising premise but deserves scrutiny. https://www.nejm.org/doi/full/10.1056/VOICESpost2600018?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/VOICESpost2600018 Paul E. Sax 2026-06-03 Lyme Disease Deserves Better — But Better Starts with Better Evidence Ensitrelvir reduced Covid-19 incidence 67% in household contacts of active cases. https://www.nejm.org/doi/full/10.1056/VOICESpost2600015?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/VOICESpost2600015 Paul E. Sax 2026-05-20 An Oral Preventive Strategy for Covid-19 that Actually Works The hantavirus outbreak has raised two major concerns for Dr. Paul Sax — and neither is directly related to the outbreak itself. https://www.nejm.org/doi/full/10.1056/VOICESpost2600014?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/VOICESpost2600014 Paul E. Sax 2026-05-11 What Worries Me Most Right Now About the Hantavirus Outbreak In a personal remembrance, Paul Sax reflects what it was like to be a resident when Dr. Eugene Braunwald was the Chair of Medicine. https://www.nejm.org/doi/full/10.1056/VOICESpost2600013?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/VOICESpost2600013 Paul E. Sax 2026-05-07 A Personal Tribute to the “Father of Modern Cardiology” Staph aureus in an unexpected place, sinus fungal balls, “explosive pleuritis”, and other lessons from 2 weeks on the consult service https://www.nejm.org/doi/full/10.1056/VOICESpost2600012?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/VOICESpost2600012 Paul E. Sax 2026-05-01 ID Link-o-Rama: On Service Edition Doravirine/islatravir has been approved by the FDA for use in stable patients with HIV but has no major advantages over existing options. https://www.nejm.org/doi/full/10.1056/VOICESpost2600010?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/VOICESpost2600010 Paul E. Sax 2026-04-23 Newly Approved HIV Treatment Option Is No More Than Fine — and Shows Just How Good HIV Treatment Is Today The same sample can have strikingly different test results, depending on the companies doing the testing. https://www.nejm.org/doi/full/10.1056/VOICESpost2600008?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/VOICESpost2600008 Paul E. Sax 2026-04-10 What Are Those At-Home Microbiome Tests Actually Telling You? Why aren’t we using it? https://www.nejm.org/doi/full/10.1056/VOICESpost2600007?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/VOICESpost2600007 Paul E. Sax 2026-04-02 One-Month Treatment for Latent Tuberculosis The number of referrals to ID doctors for this condition has exploded. What happened? https://www.nejm.org/doi/full/10.1056/VOICESpost2600005?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/VOICESpost2600005 Paul E. Sax 2026-03-25 How Latent TB Migrated from Primary to Specialty Care